Core Viewpoint - Compass Diversified has issued a warning regarding the reliability of its financial statements for fiscal years 2022, 2023, and 2024 due to expanded accounting irregularities at its subsidiary, Lugano Holding [1][5][6]. Group 1: Financial Irregularities - The company filed a report with the SEC on June 25, 2025, indicating that investors should not rely on previously issued financial statements for the fiscal years ended December 31, 2022, and 2023 [1][5]. - The identified irregularities at Lugano Holding also affected the financial statements for the fiscal year ended December 31, 2024, necessitating a restatement [4][6]. - The irregularities involved violations of applicable accounting rules and industry practices concerning financing, accounting, and inventory procedures [9]. Group 2: Legal Actions - Following the disclosure of accounting irregularities, several class-action lawsuits have been initiated against Compass Diversified, with the lead plaintiff deadline set for July 8, 2025 [3][4]. - The amended complaint in the case Moreno v. Compass Group Diversified Holdings LLC seeks to represent investors who purchased shares during the expanded class period from February 24, 2022, to May 7, 2025 [3][4]. - Hagens Berman, a law firm, is conducting an investigation into potential securities violations by Compass Diversified [8]. Group 3: Market Reaction - The market reacted severely to the news of the accounting irregularities, with Compass Diversified's stock price plummeting by more than 62% following the announcement [7].

Core Viewpoint - Aldeyra Therapeutics, Inc. is under investigation for potential violations of federal securities laws following the failure of its Phase III clinical trial for reproxalap, which was intended to treat dry eye disease [1][4]. Company Overview - Aldeyra Therapeutics is a biotechnology company focused on developing therapies for immune-mediated and metabolic diseases, with reproxalap as its lead drug candidate for dry eye disease [2]. Clinical Trial Results - The company announced positive results from its Phase III dry eye chamber clinical trial, claiming the results were "uniquely supportive" and met FDA requirements for New Drug Application (NDA) resubmission [3]. - However, the trial ultimately failed to demonstrate the efficacy of reproxalap in treating ocular symptoms associated with dry eyes, with methodological issues identified in the trial data [4]. Regulatory Response - On April 3, 2025, the FDA issued a Complete Response Letter for the NDA for reproxalap, stating that the application "failed to demonstrate efficacy in adequate and well-controlled studies" [5]. - The FDA highlighted concerns regarding the trial data, particularly methodological issues such as differences in baseline scores across treatment arms [5]. Market Reaction - Following the FDA's announcement, Aldeyra Therapeutics' stock price plummeted nearly 75% in a single trading day, dropping from a closing price of $5.33 per share on April 2, 2025 [5].

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. Why is Aldeyra Therapeutics being Investigated? Aldeyra Therapeutics is a biotechnology company focused o ...